Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CNTX with free AI briefings, catalyst countdowns, and dilution alerts.

CNTX · Context Therapeutics Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$34.4M Cash on Hand
15.2mo Cash Runway
Follow CNTX by email Get an email when CNTX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CNTX, unsubscribe in one click. Privacy

📣 What CNTX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Extended-release Onapristone Refractory Endometrial Adenocarcinoma Phase 2 · NCT04719273 Completed
Onapristone Breast Cancer Phase 1/2 · NCT05618613 Terminated
Onapristone ER Granulosa Cell Ovarian Cancer Phase 2 · NCT03909152 Completed
CT-202 Triple Negative Breast Cancer (TNBC) Phase 1 · NCT07545122 Recruiting
Anti-mesothelin T-cell Engaging Bispecific… Mesothelin-Expressing Tumors Phase 1 · NCT06756035 Terminated
Anti-CLDN6/CD3 Bispecific Antibody CTIM-76 Platinum-resistant Ovarian Cancer Phase 1 · NCT06515613 Recruiting

Also used in these trials (approved or third-party drugs, not CNTX's own candidates): Anastrozole, Elacestrant, Fulvestrant, Letrozole, Palbociclib.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CNTX holds $34.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $6.8M/quarter from operations, an estimated runway of 15.2 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 58 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CNTX files for a raise →

👥 Who Owns CNTX

Insiders 1.4% Institutions (111 holders) 63.4% Public and other holders 35.2%
HolderTypeShares% of sharesAs of
Avidity Partners Management LP Institution (13G, 5%+) 8,302,808 9.04% 2026-03-31
Soleus Capital Master Fund, L.P. Institution (13G, 5%+) 6,963,141 7.58% 2026-03-31
BlackRock, Inc. Institution (13G, 5%+) 6,169,250 6.71% 2026-06-30
Martin A. Lehr
Chief Executive Officer, Director · +1.91M options
Insider 1,079,891 1.18% 2025-06-09
Alex C. Levit
Chief Legal Officer, Corp. Sec · +773,415 options
Insider 81,983 0.09% 2025-06-06
Jennifer Lynn Minai-Azary
Chief Financial Officer · +806,915 options
Insider 80,010 0.09% 2025-06-06

Share count 91,879,177 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CNTX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CNTX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.